saruparib (AZD5305) / AstraZeneca  >>  Phase 2
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
saruparib (AZD5305) / AstraZeneca
2022-000776-19: Master Protocol of Dato-DXd as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours Protocolo Maestro de Dato-DXd en Monoterapia y en Combinación con Agentes Antineoplásicos en Pacientes con Tumores Sólidos en Estadio Avanzado o Metastásico

Not yet recruiting
2
670
Europe
AZD5305, Durvalumab, Datopotamab deruxtecan, Capecitabine, Flourouracil (5-FU), Bevacizumab, Carboplatin, leucovorin, Nivolumab, AZD5305, MEDI4736, DS-1062a, Film-coated tablet, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Solution for injection, MVASI, Prednisolone
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Various Advanced/Metastatic solid tumour types- Endometrial Cancer - Gastric Cancer - Ovarian Cancer- Metastatic castration-resistant prostate cancer- Colorectal cancer Varios tipos de tumores sólidos avanzados/metastásicos- Cáncer endometrial- Cáncer gástrico- Cáncer de ovario- Cáncer de próstata metastásico resistente a la castración- Cáncer colorrectal, Metastatic Cancer, Multiple cancers Cáncer metastásico, Múltiples cánceres, Diseases [C] - Cancer [C04]
 
 
TROPION-PanTumor03, NCT05489211 / 2022-000776-19: Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours

Calendar Jan 2024 - Dec 2024: Data from TROPION-PanTumor03 trial for advanced solid tumors
Recruiting
2
531
Europe, Canada, Japan, US, RoW
Datopotamab deruxtecan (Dato-DXd), DS-1062a, Saruparib, AZD5305, Durvalumab, MEDI4736, IMFINZI, Capecitabine, Xeloda, 5-Fluorouracil, Adrucil, Volrustomig, MEDI5752, Carboplatin, Paraplatin, Leucovorin LV, Folinic acid, Bevacizumab, Avastin, Rilvegostomig, AZD2936, Prednisone/ prednisolone, Prednisolone
AstraZeneca, Daiichi Sankyo
Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
08/26
08/26
2020-002688-77: Study of AZD5305 as monotherapy and with anti-cancer agents in patients with advanced solid malignancies

Not yet recruiting
1/2
867
RoW, Europe
AZD5305 film-coated tablets, Carboplatin, Paclitaxel, AZD5305, Not answered, Tablet, Infusion, Carboplatin, Paclitaxel
AstraZeneca AB, AstraZeneca AB
Advanced Solid Tumors, Cancer, Diseases [C] - Cancer [C04]
 
 
2021-006289-19: A study to assess safety, efficacy and pharmacokinetics of AZD5305 when given in combination with new hormonal agents in patients with Metastatic Prostate Cancer Studio per valutare sicurezza, efficacia e farmacocinetica di AZD5305 quando somministrato in combinazione con nuovi agenti ormonali in pazienti con carcinoma prostatico metastatico

Not yet recruiting
1/2
140
Europe
Darolutamide, Abiraterone Acetate, -, Enzalutamide, [-], [AZD5305], Film-coated tablet, Capsule, soft, Nubeqa 300 mg compresse rivestite con film, Zytiga, Xtandi
ASTRAZENECA AB, AstraZeneca AB
Metastatic Prostate Cancer Carcinoma prostatico metastatico, Cancer of prostate gland that spreads to different parts of body (metastatic) in men Cancro della ghiandola prostatica che si diffonde in diverse parti del corpo (metastatico) negli uomini, Diseases [C] - Cancer [C04]
 
 
D5330C00004, NCT02264678: Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Calendar Jan 2023 - Dec 2024: Data from trial for solid tumors
Recruiting
1/2
466
Europe, Canada, US, RoW
Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab, Administration of ceralasertib monotherapy, Administration of ceralasertib and olaparib, Administration of ceralasertib and durvalumab, Administration of ceralasertib in combination with AZD5305, Administration of ceralasertib in combination with carboplatin
AstraZeneca
Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
08/26
08/26
PETRA, NCT04644068: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Calendar Jan 2024 - Dec 2024: Data from PETRA trial for advanced solid malignancies
Recruiting
1/2
804
Europe, Canada, Japan, US, RoW
AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd, Camizestrant
AstraZeneca
Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5
12/26
12/26
FONTANA, NCT05797168: Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

Recruiting
1/2
150
Europe, Canada, Japan, US, RoW
AZD5335, AZD5305
AstraZeneca
Ovarian Cancer, Lung Adenocarcinoma
11/27
11/27
PETRANHA, NCT05367440: Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

Calendar Jan 2024 - Dec 2024: Data from PETRANHA trial for metastatic prostate cancer
Recruiting
1/2
172
Europe, US, RoW
AZD5305, Enzalutamide, Xtandi, Abiraterone Acetate, Zytiga, Darolutamide, Nubeqa, Apalutamide, Erleada
AstraZeneca, Bayer
Metastatic Prostate Cancer
08/30
08/30

Download Options